Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Albers Jeffrey W.	2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [ BPMC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) CEO and President
(Last)          (First)          (Middle) C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET	3. Date of Earliest Transaction (MM/DD/YYYY) 11/16/2020
(Street) CAMBRIDGE, MA 02139 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/16/2020		M(1)		20000	A	$8.80	161434	D
Common Stock	11/16/2020		S(1)		4127	D	$100.11 (2)	157307	D
Common Stock	11/16/2020		S(1)		4869	D	$99.55 (3)	152438	D
Common Stock	11/16/2020		S(1)		4483	D	$98.13 (4)	147955	D
Common Stock	11/16/2020		S(1)		6521	D	$97.61 (5)	141434	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.80	11/16/2020		M (1)			20000	(6)	2/10/2025	Common Stock	20000	$0	22170	D

Explanation of Responses:
(1)	Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
(2)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.93 to $100.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 to 5 to this form 4.
(3)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.02 to $99.92 per share.
(4)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.90 to $98.89 per share.
(5)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.15 to $97.89 per share.
(6)	This option was granted on February 10, 2015 and is fully vested as of the date hereof.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Albers Jeffrey W. C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE, MA 02139	X		CEO and President

Signatures
/s/ Christopher Frankenfield, Attorney-in-Fact		11/18/2020
**Signature of Reporting Person		Date